M-J. Ahn

机构：Samsung Medical Center, Sungkyunkwan University

发表论文 112 篇 · 总被引 1213 次 · h-index 17

代表论文

• Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study (2025 · Annals of Oncology · 被引 43)
• 2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi (2025 · Journal of Thoracic Oncology · 被引 11)
• LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study (2025 · Journal of Thoracic Oncology · 被引 9)
• OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update (2024 · Journal of Thoracic Oncology · 被引 9)
• PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC (2024 · Journal of Thoracic Oncology · 被引 8)
• 630MO First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort (2024 · Annals of Oncology · 被引 4)